Iron infusions in the community

Size: px
Start display at page:

Download "Iron infusions in the community"

Transcription

1 i NOTIFICATION Iron infusions in the community 11 September 2017 What we re doing Eligible people will now be able to receive ferric carboxymaltose iron infusions in some general practitioners clinics or other community based settings. We re pleased to inform you about our decision to list ferric carboxymaltose (Ferinject) 50 mg per ml, 10 ml vial in Section B (Community) of the Pharmaceutical Schedule. Patients will need to meet the Special Authority criteria to be eligible to receive the funded medicine. Any changes to the original proposal? This was the subject of a consultation letter dated 2 June 2017, and having carefully considered consultation feedback, we have made the following changes: the decision will take effect from 1 October 2017; and amendments to the proposed access criteria to: o remove the requirement to trial oral iron for some clinical circumstances; and o remove the ferritin limit for applications made by specialists (or on the recommendation of a specialist). Who we think will be most interested This decision will be of interest to community and hospital clinicians, internal medicine physicians, anaesthetists, surgeons, and general practitioners. hospital and community pharmacists, DHBs, suppliers and wholesalers. patients who currently travel to hospital to have an iron infusion in an outpatient setting. A PHARMAC NOTIFICATION 1

2 What will the effect of this decision be? This decision is expected to improve patient health outcomes by providing funded access to ferric carboxymaltose (Ferinject) in primary care. DHBs may gain value from reduced hospital pharmaceutical expenditure, reduced use of blood products related to surgery and reduced demand on hospital outpatient infusion clinics. For patients From 1 October 2017 patients that meet the Special Authority criteria will be eligible for funded ferric carboxymaltose. Ferric carboxymaltose will be dispensed by a community pharmacy on presentation of a prescription. In some cases patients might need to collect it from the pharmacy prior to the administration date and take it with them to the appointment, in others the health service will arrange this. Service availability and costs may also differ between regions, so patients should discuss these matters with their doctor. For community pharmacies From 1 October 2017, pharmacies will be able to dispense ferric carboxymaltose, fully funded, to patients with a valid Special Authority approval. Pharmacies may wish to ask their local general practices if they are providing iron infusions. For hospital pharmacies From 1 October 2017, ferric carboxymaltose will be funded, when dispensed to patients with a valid Special Authority approval. Reimbursement claims can be made (electronically or manually) by pharmacies with a community pharmacy contract claimant number. The Ferinject brand was listed in Section H of the Pharmaceutical Schedule, for inpatient and outpatient use, from 1 August There are no changes to the Section H restrictions. For prescribers From 1 October 2017, ferric carboxymaltose will be funded, subject to Special Authority criteria. A Special Authority can be applied for electronically or manually and the approval number should be printed on the prescription. Prescribers and practices will need to liaise with their DHB regarding delivery of community based infusion services in the DHB region and any accreditation that might be required for a practice to provide DHB funded infusion services. Patients should be advised if there are likely any service charges applicable. PHARMAC notes that the Special Authority criteria are not a clinical guideline for the use of ferric carboxymaltose and the management of iron deficiency anaemia. Prescribers are encouraged to reference their local DHB health pathways (or equivalent guideline) for the management of iron deficiency anaemia. PHARMAC intends to provide support materials for general practice on the management of chronic anaemia and the use of ferric carboxymaltose. For DHBs From 1 October 2017, DHBs will fund the pharmaceutical cost of ferric carboxymaltose for community patients via the Combined Pharmaceutical Budget (managed by A PHARMAC NOTIFICATION 2

3 PHARMAC). PHARMAC has provided supplementary information to DHBs to support this change. Detail of this decision Ferric carboxymaltose (Ferinject) will be listed in Section B of the Pharmaceutical Schedule at the following price and subsidy (ex-manufacturer, excluding GST): Chemical Presentation Brand Pack size Ferric carboxymaltose Inj 50 mg per ml, 10 ml vial Price and subsidy Ferinject 1 $ A confidential rebate will apply to Ferinject, reducing its net price to the Funder (DHBs). Ferric carboxymaltose (Ferinject) will be listed in Section B, subject to the following Special Authority eligibility criteria: Initial application (serum ferritin less than or equal to 20 mcg/l) from any medical practitioner. Approval valid for 3 months for applications meeting the following criteria: 1. Patient has been diagnosed with iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/l; and 2. Any of the following: 2.1.Patient has been compliant with oral iron treatment and treatment has proven ineffective; or 2.2.Treatment with oral iron has resulted in dose-limiting intolerance; or 2.3.Rapid correction of anaemia is required. Renewal (serum ferritin less than or equal to 20 mcg/l) from any medical practitioner. Approval valid for 3 months for applications meeting the following criteria: 1. Patient continues to have iron-deficiency anaemia with a serum ferritin level of less than or equal to 20 mcg/l; and 2. A re-trial with oral iron is clinically inappropriate. Initial application (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or a medical practitioner on the recommendation of an internal medicine physician, obstetrician, gynaecologist or anaesthetist. Approval valid for 3 months for applications meeting the following criteria: 1. Patient has been diagnosed with iron-deficiency anaemia; and 2. Any of the following: 2.1. Patient has been compliant with oral iron treatment and treatment has proven ineffective; or 2.2.Treatment with oral iron has resulted in dose-limiting intolerance; or 2.3.Patient has symptomatic heart failure, chronic kidney disease stage 3 or more or active inflammatory bowel disease and a trial of oral iron is unlikely to be effective; or 2.4.Rapid correction of anaemia is required. Renewal (iron deficiency anaemia) only from an internal medicine physician, obstetrician, gynaecologist, anaesthetist or a medical practitioner on the recommendation of an internal medicine physician, obstetrician, gynaecologist or anaesthetist. Approval valid for 3 months for applications meeting the following criteria: 1. Patient continues to have iron-deficiency anaemia; and 2. A re-trial with oral iron is clinically inappropriate. A PHARMAC NOTIFICATION 3

4 For the avoidance of doubt, iron polymaltose will remain listed in both Section B and Section H of the Pharmaceutical Schedule, and iron sucrose will remain listed in Section H. Therefore, clinicians can continue to choose which iron preparation to prescribe, depending on the clinical situation. Our response to what you told us We re really grateful for the time people took to respond to this consultation. All consultation responses received by 21 June 2017 were considered in their entirety when making a decision. The table below summarises the main themes raised in feedback, any changes we have made after listening to you, and other comments on the feedback. If you have any questions, you can us at enquiry@pharmac.govt.nz or call our toll free number (9 am to 5 pm, Monday to Friday) on Theme The Special Authority criteria is very permissive. PHARMAC Comment We are aware that the criteria cover a large patient group and this has been taken into account in our budget impact assessment and forecasting. Evidence was provided to support that a trial of oral iron should not be required first in patients who do not absorb oral iron effectively namely patients with: chronic kidney disease active IBD symptomatic heart failure Patients in general practice that have upcoming surgery should be able to be initiated by a GP and GPs should be entitled to apply for patients with a ferritin >20mcg/L. Haemoglobin thresholds should be included. The requirement for anaemia should be removed for heart failure patients (those with a ferritin under 300 mcg/l are treated) The cause of iron deficiency should be stated on the special authority form. The proposed Special Authority criteria have been amended following consideration of this feedback. Pre-surgical patients will be eligible under criterion 2.3 for rapid correction of anaemia which does not include a timeframe as this should be determined by the treating clinician. Pre-surgical patients with a ferritin greater than 20 mcg/l would be under the care of a specialist and the treating specialist could provide the GP a treatment plan (a recommendation) as to when an iron infusion would be appropriate. PHARMAC sought clinical advice on Special Authority criteria and both PTAC and the Haematology Subcommittee considered haemoglobin levels for inclusion, however the recommendation provided was for criteria that was not inhibitive to different patient groups. PHARMAC considers that removing the requirement for diagnosis with iron-deficiency anaemia would be a much larger group of patients than we have assessed. We intend to seek advice on this feedback from the relevant PTAC Subcommittee. PHARMAC notes that the Special Authority is not intended as a clinical guideline. PHARMAC agrees that the cause for iron deficiency anaemia should be investigated by the treating clinician as part of best practice and recorded in the patient s notes; but we do not consider it should be a criterion for accessing funding. A PHARMAC NOTIFICATION 4

5 Theme Consumables were not included in the proposal and these are also not available on a PSO. There is no clear mechanism for getting the medicine to general practice (uncollected, collected but failed to go to GP, unclear medicolegal accountability for follow ups when non-collection or no-show). Not all GP practices will have the capability and capacity to deliver an infusion service. Some patients may have to find a provider other than their usual GP. Some DHBs are underway with their planning for community infusion services, others are not and considered that the proposed 1 August 2017 list date was not enough time to plan for such a transition. Some DHBs noted that they have not allocated budget for this service to be provided in the community and noted that reducing hospital based infusions may appear as a saving but this does not produce monetary saving for the hospital. If a patient charge was applicable to either the medicine ($5 pharmacy co-payment) or the service/administration (which could be more than $100) this could lead to inequities based on a patient s ability to pay. One DHB considered there was a National policy, with respect to services shifting from secondary to primary care, that they must remain free to the patient. PHARMAC Comment PHARMAC considers that the cost of consumables would be part of the infusion service costs. PHARMAC note that utilising pharmacy for the distribution of ferric carboxymaltose was the only current option available to progress funding in the community setting via a claiming and reimbursement model. PHARMAC acknowledges that it is unlikely that all general practices will provide infusion services, we note that an increasing number of general practices are providing infusions for patients. DHBs that have systems in place now will have no barrier to accessing funded pharmaceutical in the community. Those that are not able to offer funded community based infusions are not required to be ready on 1 October These DHBs can continue to provide patients with ferric carboxymaltose in a hospital outpatient setting, or as alternatively arranged, as they are currently doing. DHB Hospitals will be able to claim reimbursement for the cost of the pharmaceutical for hospital outpatients who have Special Authority approvals via the Combined Pharmaceutical Budget, reducing DHB Hospitals pharmaceutical expenditure. Additionally, where services shift from hospital to the community setting, hospital pharmaceutical expenditure would also reduce although the cost to the funder would remain. PHARMAC acknowledges that freeing up infusion capacity is not realised as monetary savings for DHB Hospitals. Noted. This issue was also raised during the 2014 consultation on the hospital listing and PHARMAC committed to engaging with stakeholders to discuss this further. Since 2014 PHARMAC has explored whether a community based funding and reimbursement model for pharmaceuticals delivered in primary care could be developed. As yet this has not been resolved. PHARMAC is now in a budget position to progress a community listing and intends to continue engaging with relevant health sector stakeholders about development of a community based claiming and reimbursement model for pharmaceuticals. There are no changes to the Section H restrictions for hospitals. Therefore, eligible patients could continue to access funded ferric carboxymaltose treatment via DHB hospitals in outpatient clinics if community infusions services are cost prohibitive. Noting that inexpensive oral and intramuscular forms of iron will still be available for clinicians to provide. This decision would not change any current expectations or Crown funding agreements in place regarding DHB service provision charges. PHARMAC anticipates that DHBs would have regard to any such expectations when developing options for local service provision. A PHARMAC NOTIFICATION 5

6 Theme This proposal does not address what training in or accreditation is required. PHARMAC Comment PHARMAC will be engaging with primary care to develop educational materials to support the introduction of ferric carboxymaltose via agreements with Goodfellow and BPAC. A PHARMAC NOTIFICATION 6

Why Iron? Iron is the Most prevalent micronutrient deficiency in the world (WHO 1968)

Why Iron? Iron is the Most prevalent micronutrient deficiency in the world (WHO 1968) Why Iron? Iron is the Most prevalent micronutrient deficiency in the world (WHO 1968) Iron deficiency anaemia is a Major reason for blood being transfused Iron deficiency without anaemia is 3 times as

More information

Request for information on a proposal to fund compression bandages and hosiery for the treatment of venous leg ulcers

Request for information on a proposal to fund compression bandages and hosiery for the treatment of venous leg ulcers 24 May 2013 Request for information on a proposal to fund compression bandages and hosiery for the treatment of venous leg ulcers PHARMAC is interested in receiving information from suppliers, DHBs, service

More information

REQUEST FOR PROPOSALS SUPPLY OF FENTANYL TRANSDERMAL PATCHES. PHARMAC invites proposals for the supply of fentanyl transdermal patches in New Zealand.

REQUEST FOR PROPOSALS SUPPLY OF FENTANYL TRANSDERMAL PATCHES. PHARMAC invites proposals for the supply of fentanyl transdermal patches in New Zealand. 2 August 2007 Dear Supplier REQUEST FOR PROPOSALS SUPPLY OF FENTANYL TRANSDERMAL PATCHES PHARMAC invites proposals for the supply of fentanyl transdermal patches in New Zealand. This request for proposals

More information

Post-operative and Discharge Pathways for PBM Claire L J Atterbury CNS Transfusion and Haematology

Post-operative and Discharge Pathways for PBM Claire L J Atterbury CNS Transfusion and Haematology Post-operative and Discharge Pathways for PBM Claire L J Atterbury CNS Transfusion and Haematology 1 Plan for the worst and hope for the best claire.atterbury@qehkl.nhs.uk 2 Where were we? What year? The

More information

NHS PCA (P) (2015) 17. Dear Colleague

NHS PCA (P) (2015) 17. Dear Colleague Healthcare Quality and Strategy Directorate Pharmacy and Medicines Division Dear Colleague PHARMACEUTICAL SERVICES AMENDMENTS TO DRUG TARIFF IN RESPECT OF SPECIAL PREPARATIONS AND IMPORTED UNLICENSED MEDICINES

More information

NHS PCA (P) (2015) 17 ANNEX B. Specials Frequently Asked Questions for Community Pharmacy. Pre-authorisation:

NHS PCA (P) (2015) 17 ANNEX B. Specials Frequently Asked Questions for Community Pharmacy. Pre-authorisation: ANNEX B Specials Frequently Asked Questions for Community Pharmacy Pre-authorisation: Q: When do I need to seek authorisation? A: You need to seek authorisation for all Specials manufactured medicines

More information

South East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide

South East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide South East London Interface Prescribing Policy including the NHS and Private Interface Prescribing Guide 1. Introduction 1.1 This policy has been developed by the South East London Clinical Commissioning

More information

Improving compliance with oral methotrexate guidelines. Action for the NHS

Improving compliance with oral methotrexate guidelines. Action for the NHS Patient safety alert 13 Alert Immediate action Action Update Information request Ref: NPSA/2006/13 Improving compliance with oral methotrexate guidelines Oral methotrexate is a safe and effective medication

More information

Local Implementation Plan for Supply of Stoma Appliances in the Community from April Draft. Version 1 October

Local Implementation Plan for Supply of Stoma Appliances in the Community from April Draft. Version 1 October Local Implementation Plan for Supply of Stoma Appliances in the Community from April 2006 Draft Version 1 October 2005 1 Contents Background National Procurement and Funding Status of Sponsored or Company

More information

GENERAL INFORMATION INDEX

GENERAL INFORMATION INDEX INDEX INDEX...3 GENERAL... 4 1. SCOPE & APPLICATION OF THE SCOTTISH DRUG TARIFF... 4 2. FREQUENCY OF PUBLICATION... 5 3. DETAILS OF AMENDMENTS SINCE LAST PUBLISHED EDITION... 5 4. REQUIREMENT ON NHS BOARDS

More information

Population. 4.1 million People Maori 14% Pacific People 6% Asian 6% 39.9 million sheep

Population. 4.1 million People Maori 14% Pacific People 6% Asian 6% 39.9 million sheep Population 4.1 million People Maori 14% Pacific People 6% Asian 6% 39.9 million sheep Paul Cressey The New Zealand Health System New Zealand Health Information emedicine NZ Context Safe Medication Management

More information

Recommendations from National Patient Safety Agency alerts that remain relevant to the Never Events list 2018

Recommendations from National Patient Safety Agency alerts that remain relevant to the Never Events list 2018 Recommendations from National Patient Safety Agency alerts that remain relevant to the Never Events list 2018 January 2018 We support providers to give patients safe, high quality, compassionate care within

More information

Chapter 3 Products, Networks, and Payment Unit 4: Pharmacy and Formulary

Chapter 3 Products, Networks, and Payment Unit 4: Pharmacy and Formulary Chapter 3 Products, Networks, and Payment Unit 4: Pharmacy and Formulary In This Unit Topic See Page Unit 4: Pharmacy and Formulary Pharmaceutical Overview 2 Pharmaceutical 3 Drug 4 NOTE: This section

More information

Chapter 2 Provider Responsibilities Unit 6: Behavioral Health Care Specialists

Chapter 2 Provider Responsibilities Unit 6: Behavioral Health Care Specialists Chapter 2 Provider Responsibilities Unit 6: Health Care Specialists In This Unit Unit 6: Health Care Specialists General Information 2 Highmark s Health Programs 4 Accessibility Standards For Health Providers

More information

RULES OF TENNESSEE DEPARTMENT OF LABOR AND WORKFORCE DEVELOPMENT WORKERS COMPENSATION DIVISION

RULES OF TENNESSEE DEPARTMENT OF LABOR AND WORKFORCE DEVELOPMENT WORKERS COMPENSATION DIVISION RULES OF TENNESSEE DEPARTMENT OF LABOR AND WORKFORCE DEVELOPMENT WORKERS COMPENSATION DIVISION CHAPTER 0800-02-25 WORKERS COMPENSATION MEDICAL TREATMENT TABLE OF CONTENTS 0800-02-25-.01 Purpose and Scope

More information

NPSA Alert 03: Reducing the harm caused by oral Methotrexate. Implementation Progress Report July Learning and Sharing

NPSA Alert 03: Reducing the harm caused by oral Methotrexate. Implementation Progress Report July Learning and Sharing NPSA Alert 03: Reducing the harm caused by oral Methotrexate Implementation Progress Report July 2006 Learning and Sharing CONTENTS Page 1 Background 3 2 Findings 4 Appendix 1 Summary of responses 6 Appendix

More information

Prescribing Controlled Drugs: Standard Operating Procedure

Prescribing Controlled Drugs: Standard Operating Procedure Clinical Prescribing Controlled Drugs: Standard Operating Procedure Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation

More information

78th OREGON LEGISLATIVE ASSEMBLY Regular Session. House Bill 2028 SUMMARY

78th OREGON LEGISLATIVE ASSEMBLY Regular Session. House Bill 2028 SUMMARY Sponsored by COMMITTEE ON HEALTH CARE th OREGON LEGISLATIVE ASSEMBLY-- Regular Session House Bill SUMMARY The following summary is not prepared by the sponsors of the measure and is not a part of the body

More information

Physician Payments Disclosure and Aggregate Spend:

Physician Payments Disclosure and Aggregate Spend: Physician Payments Disclosure and Aggregate Spend: Navigating Conflicting and Unclear State Laws and Regulations A Guide for Device Manufacturers October 26, 2010 Colin J. Zick Foley Hoag LLP czick@foleyhoag.com

More information

Clinical pharmacists in general practice links with community pharmacy

Clinical pharmacists in general practice links with community pharmacy Introduction Pharmacists employed in the GP clinical pharmacist NHS England programme are encouraged to complete online activity recording. One of the activities records how they are working with community.

More information

PHARMAC has withheld some material from this Minute in accordance with section 6a of the Official Information Act 1982

PHARMAC has withheld some material from this Minute in accordance with section 6a of the Official Information Act 1982 PHARMAC has withheld some material from this Minute in accordance with section 6a of the Official Information Act 1982 Minutes of the PHARMAC Consumer Advisory Committee (CAC) meeting Friday 6 March 2009

More information

Safer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS

Safer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS Safer use of anticoagulants: the NPSA patient safety alert Steve Chaplin MSc, MRPharmS Steve Chaplin describes the NPSA s anticoagulant patient safety alert and the measures it recommends for making the

More information

National clinical audit of inpatient care for adults with ulcerative colitis

National clinical audit of inpatient care for adults with ulcerative colitis National clinical audit of inpatient care for adults with ulcerative colitis UK inflammatory bowel disease (IBD) audit Executive summary report June 2014 Prepared by the Clinical Effectiveness and Evaluation

More information

SCHEDULE 2 THE SERVICES

SCHEDULE 2 THE SERVICES SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. 170008/S Service Atypical haemolytic uraemic syndrome (ahus) (all ages) Commissioner Lead Provider Lead Period Date of Review

More information

Quality Medication Use in Aboriginal Communities

Quality Medication Use in Aboriginal Communities Quality Medication Use in Aboriginal Communities Lance Emerson, Kathy Bell, Roland Manning 5th National Rural Health Conference Adelaide, South Australia, 14-17th March 1999 Lance Emerson Proceedings Quality

More information

Oxfordshire Anticoagulation Service. Important information about anticoagulation with vitamin K antagonists Information for patients

Oxfordshire Anticoagulation Service. Important information about anticoagulation with vitamin K antagonists Information for patients Oxfordshire Anticoagulation Service Important information about anticoagulation with vitamin K antagonists Information for patients Page 2 Your information Name:... Address:......... or patient stickie

More information

Pharmacist (Palliative Care) December 2014 Page 1

Pharmacist (Palliative Care) December 2014 Page 1 Job Profile Job Title: Department: Main Location: Hospice Palliative Care Pharmacist 7 NHS (8SRC) Less than full time(0.8) Full time equivalent around 36,300 Head of Clinical Services 1. Main Purpose of

More information

Number and costs of prescription items

Number and costs of prescription items Number of prescritpion items (m) Cost of prescriptions ( m) HSC Efficiencies - Prescribing in primary/secondary care 1 Introduction 1.1 Purpose It has been reported that there is an expected overspend

More information

Minutes of the PHARMAC Consumer Advisory Committee (CAC) meeting Wednesday 24 October 2012

Minutes of the PHARMAC Consumer Advisory Committee (CAC) meeting Wednesday 24 October 2012 Minutes of the PHARMAC Consumer Advisory Committee (CAC) meeting Wednesday 24 October 2012 The meeting was held at PHARMAC, 9th floor, 40 Mercer St, Wellington from 9.45 am. Present: Kate Russell Anne

More information

Corporate/General Finance

Corporate/General Finance Document title: Policy and Guidance for Joint Working with the Pharmaceutical Industry (including rebate schemes) & Commercial Sponsorship of Meetings/Training Events CCG document ref: Author / originator:

More information

SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY

SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY 1 SUMMARY This document sets out Haringey Clinical Commissioning Group policy and advice to employees on sponsorship and joint working with

More information

Unlicensed Medicines Policy Document

Unlicensed Medicines Policy Document Unlicensed Medicines Policy Document Effective: February 2002 (Intranet 2006) Review date: February 2007 A. Introduction In order to ensure that medicines are safe and effective the manufacture and sale

More information

Outcomes from the Business Case Sub Committee 8 th February 2013

Outcomes from the Business Case Sub Committee 8 th February 2013 Outcomes from the Business Case Sub Committee 8 th February 2013 Business Case Summary Committee Decision Designated Nurse Child Transfer of post from Your Healthcare (YHC) to Safeguarding Kingston CCG.

More information

Guidelines for patients undergoing surgery as part of an Enhanced Recovery Programme (ERP)

Guidelines for patients undergoing surgery as part of an Enhanced Recovery Programme (ERP) Guidelines for patients undergoing surgery as part of an Enhanced Recovery Programme (ERP) Summary Helping you to get better sooner after surgery June 2012 Foreword These guidelines have been produced

More information

MEDICINES RECONCILIATION GUIDELINE Document Reference

MEDICINES RECONCILIATION GUIDELINE Document Reference MEDICINES RECONCILIATION GUIDELINE Document Reference G358 Version Number 1.01 Author/Lead Job Title Jackie Stark Principle Pharmacist Clinical Services Date last reviewed, (this version) 29 November 2012

More information

Best Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland. patient CMP

Best Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland. patient CMP Best Practice Guidance for Supplementary Prescribing by Nurses Within the HPSS in Northern Ireland patient CMP nurse doctor For further information relating to Nurse Prescribing please contact the Nurse

More information

Legal limitations for nurse prescribers: a focus on dispensing. Andy Gray Division of Pharmacology Discipline of Pharmaceutical Sciences

Legal limitations for nurse prescribers: a focus on dispensing. Andy Gray Division of Pharmacology Discipline of Pharmaceutical Sciences Legal limitations for nurse prescribers: a focus on dispensing Andy Gray Division of Pharmacology Discipline of Pharmaceutical Sciences Outline What is prescribing? What is dispensing? Enabling legal frameworks

More information

The University of North Carolina Wilmington PHYSICIAN ASSISTANT COMPETENCY PROFILE

The University of North Carolina Wilmington PHYSICIAN ASSISTANT COMPETENCY PROFILE The University of North Carolina Wilmington PHYSICIAN ASSISTANT COMPETENCY PROFILE Description of Work: Positions in this class provide patient evaluation and care in area of assignment. Duties include

More information

Prescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services

Prescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services Prescribing Policy between Nottinghamshire Commissioning Organisations and local providers of NHS Services Document Purpose Version 2.2 To detail the specific contractual issues associated with prescribing

More information

Definitions: In this chapter, unless the context or subject matter otherwise requires:

Definitions: In this chapter, unless the context or subject matter otherwise requires: CHAPTER 61-02-01 Final Copy PHARMACY PERMITS Section 61-02-01-01 Permit Required 61-02-01-02 Application for Permit 61-02-01-03 Pharmaceutical Compounding Standards 61-02-01-04 Permit Not Transferable

More information

NON-MEDICAL PRESCRIBING POLICY

NON-MEDICAL PRESCRIBING POLICY NON-MEDICAL PRESCRIBING POLICY To be read in conjunction with the Medicines Policy, Controlled Drug Policy and the FP10 Prescribing Forms Policy Version: 5 Date of issue: August 2017 Review date: August

More information

Using Practitioner Supply Orders and Standing Orders in the Rheumatic Fever Prevention Programme. Guidance for sore throat management services

Using Practitioner Supply Orders and Standing Orders in the Rheumatic Fever Prevention Programme. Guidance for sore throat management services Using Practitioner Supply Orders and Standing Orders in the Rheumatic Fever Prevention Programme Guidance for sore throat management services February 2015 Citation: Ministry of Health. 2015. Using Practitioner

More information

LSU First & WebTPA: Working Together

LSU First & WebTPA: Working Together LSU First & WebTPA: Working Together 2016 LSU First Health Plan Changes 2016 LSU First Health Plan Changes New ID Card Specialty drug copay $150 90 day timely filing period (medical and pharmacy) Home

More information

Alert. Patient safety alert. Actions that can make anticoagulant therapy safer. 28 March Action for the NHS and the independent sector

Alert. Patient safety alert. Actions that can make anticoagulant therapy safer. 28 March Action for the NHS and the independent sector Patient safety alert 18 Alert 28 March 2007 Immediate action Action Update Information request Ref: NPSA/2007/18 Actions that can make anticoagulant therapy safer Anticoagulants are one of the classes

More information

FUNDING FOR TREATMENT IN THE EEA APPLICATION FORM

FUNDING FOR TREATMENT IN THE EEA APPLICATION FORM FUNDING FOR TREATMENT IN THE EEA APPLICATION FORM Please note: NHS England can only process claims for residents ordinarily resident in England. Reimbursements will only be granted for eligible treatment

More information

The Swedish national courts administration. data/assets/pdf_file/0020/96410/e73430.pdf

The Swedish national courts administration.  data/assets/pdf_file/0020/96410/e73430.pdf Sweden European Region Updated: February 2017 This document contains links to websites where you can find national legislation and health laws. We link to official government legal sources wherever possible.

More information

Authorisation to Administer Medicines

Authorisation to Administer Medicines Authorisation to Administer Medicines Health Guidance Publication date: March 2016 This information sheet is produced for the guidance of Care Inspectorate staff only. The contents should not be regarded

More information

BioMarin Patient and Physician Support (BPPS) Enrollment Forms for KUVAN

BioMarin Patient and Physician Support (BPPS) Enrollment Forms for KUVAN BioMarin Patient and Physician Support (BPPS) Enrollment Forms for KUVAN Instructions for Completing Statement of Medical Necessity (SMN) and Prescription for KUVAN If you need assistance with the attached

More information

Newfoundland and Labrador Pharmacy Board

Newfoundland and Labrador Pharmacy Board Newfoundland and Labrador Pharmacy Board Standards of Practice Prescribing by Pharmacists August 2015 Table of Contents 1) Introduction... 1 2) Requirements... 1 3) Limitations... 1 4) Operational Standards...

More information

An Overview for F2 Doctors of Foundation Programme attachments to General Practice

An Overview for F2 Doctors of Foundation Programme attachments to General Practice An Overview for F2 Doctors of Foundation Programme attachments to General Practice July 2011 Contents Page GP Placements 2 Guidance on Educational Agreements 4 Key facts about F2 Placements 6 The Foundation

More information

Register No: Status: Public on ratification

Register No: Status: Public on ratification Private Patient Policy Type: Policy Register No: 12024 Status: Public on ratification Developed in response to: Service Development Contributes to CQC Outcome number: 4 Consulted With Post/Committee/Group

More information

Expanding Your Pharmacist Team

Expanding Your Pharmacist Team CALIFORNIA QUALITY COLLABORATIVE CHANGE PACKAGE Expanding Your Pharmacist Team Improving Medication Adherence and Beyond August 2017 TABLE OF CONTENTS Introduction and Purpose 1 The CQC Approach to Addressing

More information

Pharmacy Services within the Hospital

Pharmacy Services within the Hospital Pharmacy Services within the Hospital Pharmacy Department Clinical Support Services This leaflet has been designed to give you important information and to answer some common queries that you may have.

More information

Good Practice Principles:

Good Practice Principles: NHMC National Homecare Medicines Committee Good Practice Principles: Provision of Manufacturer Funded Homecare Medicines Services National Homecare Medicines Committee February 2018 Version 1 Definitions

More information

Responsible pharmacist requirements: What activities can be undertaken?

Responsible pharmacist requirements: What activities can be undertaken? requirements: What activities can be undertaken? Status of this document This guidance is intended to assist the profession in implementing the responsible requirements within registered premises. 1 Appendix

More information

Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE. SECTION 9(a) UNLICENSED MEDICINES

Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE. SECTION 9(a) UNLICENSED MEDICINES Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE SECTION 9(a) UNLICENSED MEDICINES BACKGROUND and PURPOSE Under the Medicines Act 1968 (EEC Directive 65/65), a company

More information

Overview of Select Health Provisions FY 2015 Administration Budget Proposal

Overview of Select Health Provisions FY 2015 Administration Budget Proposal Overview of Select Health Provisions FY 2015 Administration Budget Proposal On March 4, 2014, President Obama released his Administration s FY 2015 budget proposal to Congress. The budget contains a number

More information

Implementing QIPP in care homes Hounslow PCT approach - Delivering positive clinical and cost effective outcomes

Implementing QIPP in care homes Hounslow PCT approach - Delivering positive clinical and cost effective outcomes Implementing QIPP in care homes Hounslow PCT approach - Delivering positive clinical and cost effective outcomes Unoma Okoli Care Home Pharmacist, Hillingdon PCT unoma.okoli@nhs.net Background CHUMS-Care

More information

Scotia College of Pharmacists Standards of Practice. Practice Directive Prescribing of Drugs by Pharmacists

Scotia College of Pharmacists Standards of Practice. Practice Directive Prescribing of Drugs by Pharmacists Scotia College of Pharmacists Standards of Practice Practice Directive Prescribing of Drugs by Pharmacists September 2014 ACKNOWLEDGEMENTS This Practice Directives document has been developed by the Prince

More information

E-Prescribing, Formulary Searching and Exception Requests for MDwise Plans

E-Prescribing, Formulary Searching and Exception Requests for MDwise Plans E-Prescribing, Formulary Searching and Exception Requests for MDwise Plans E-Prescribing Together with its pharmacy benefits managers (PBMs), MedImpact and PerformRx, MDwise provides physicians and other

More information

Specialty Pharmacy How is Traditional Pharmacy Practice Positioned

Specialty Pharmacy How is Traditional Pharmacy Practice Positioned Specialty Pharmacy How is Traditional Pharmacy Practice Positioned Nick Calla Vice President, Industry Relations Cardinal Health Specialty Solutions August 19, 2016 Today s Learning Objectives Understand

More information

National Programme for IT. Ken Lunn Head of Comms and Messaging OMG/HL7 workshop October 2005

National Programme for IT. Ken Lunn Head of Comms and Messaging OMG/HL7 workshop October 2005 National Programme for IT Ken Lunn Head of Comms and Messaging OMG/HL7 workshop 25-27 October 2005 Contents Context Our aims What is the National Programme for IT? Implementation Benefits Questions In

More information

Oklahoma Health Care Authority (OHCA) Pharmacy Provider Attestation Hemophilia and Other Rare Bleeding Disorders Standards of Care

Oklahoma Health Care Authority (OHCA) Pharmacy Provider Attestation Hemophilia and Other Rare Bleeding Disorders Standards of Care Page 1 Oklahoma Health Care Authority (OHCA) Pharmacy Provider Attestation Hemophilia and Other Rare Bleeding Disorders Standards of Care In order to be reimbursed for providing factor replacement products

More information

Medicine and Supporting Pupils at School with Medical Conditions Policy

Medicine and Supporting Pupils at School with Medical Conditions Policy Medicine and Supporting Pupils at School with Medical Conditions Policy This Policy is founded within our School ethos which provides a caring, friendly and safe environment for all members of our community.

More information

Appendix 2. Community Pharmacy Emergency Hormonal Contraception Service

Appendix 2. Community Pharmacy Emergency Hormonal Contraception Service Appendix 2 Community Pharmacy Emergency Hormonal Contraception Service 2014 until end November 2016 Contents Executive Summary... 3 Aims and intended service outcomes of the service... 3 Brief service

More information

Inflammatory bowel disease service. Information for patients

Inflammatory bowel disease service. Information for patients Inflammatory bowel disease service Information for patients We ve written this leaflet to explain about our inflammatory bowel disease (IBD) service. If you have ulcerative colitis, Crohn s disease or

More information

NHS Summary Care Record. Guide for GP Practice Staff

NHS Summary Care Record. Guide for GP Practice Staff NHS Summary Care Record Guide for GP Practice Staff NHS Summary Care Record Guide for GP Practice Staff v1.2 October 2012 Table of Contents 1 Introduction to this guide...3 2 Overview of the Summary Care

More information

Save up to $4,000 a year?!

Save up to $4,000 a year?! Save up to $4,000 a year?! Indication and Usage HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is an immune globulin with a recombinant human hyaluronidase indicated

More information

JOB DESCRIPTION. Progressive: A learning organization, encouraging innovation and continuous improvement.

JOB DESCRIPTION. Progressive: A learning organization, encouraging innovation and continuous improvement. JOB DESCRIPTION Job Title: Medicines Management Support Assistant Pay Band: Band 3 Hours of Work: Responsible to: Accountable to: Base Point: Contract Type 37.5 hours per week Prescription Order Line Manager

More information

Primary & Secondary Care Interface Issues. Safety In Practice Learning Session 4 27th June 2016

Primary & Secondary Care Interface Issues. Safety In Practice Learning Session 4 27th June 2016 Primary & Secondary Care Interface Issues Safety In Practice Learning Session 4 27th June 2016 GPs feel that some referrals are not dealt with appropriately Barriers to admitting a patient acutely Long

More information

ST PAUL S CATHOLIC PRIMARY SCHOOL AND NURSERY. Supporting Pupils with Medical Conditions Policy

ST PAUL S CATHOLIC PRIMARY SCHOOL AND NURSERY. Supporting Pupils with Medical Conditions Policy ST PAUL S CATHOLIC PRIMARY SCHOOL AND NURSERY Supporting Pupils with Medical Conditions Policy Our Mission Statement Do everything with love. (St Paul s first letter to the Corinthians 16:14) This means

More information

Review of Local Enhanced Services

Review of Local Enhanced Services Review of Local Enhanced Services 1. Background and context 1.1 CCGs are required to prepare for the phasing out of LESs by April 2014 by reviewing the existing LES portfolio and developing commissioning

More information

NHS Fife. Patient Group Direction for Named Community Pharmacists to Supply

NHS Fife. Patient Group Direction for Named Community Pharmacists to Supply Patient Group Direction for Named Community Pharmacists to Supply Senna tablets 7.5mg or Senna syrup 7.5mg/5ml (Total sennosides calculated as sennoside B) For patients aged 16 years and older prescribed

More information

Audit Data Collection Form

Audit Data Collection Form pecialist Pharmacy ervice Medicines Use and afety Audit Data Collection Form Collaborative audit across England on the quality of medication related information provided when transferring patients from

More information

Appendix 1. Immediate Postpartum Long-Acting Reversible Contraception (LARC)

Appendix 1. Immediate Postpartum Long-Acting Reversible Contraception (LARC) Appendix 1. Immediate Postpartum Long-Acting Reversible Contraception (LARC) Program Implementation Guide: Exploration Stage Implementation Guide Overview Each stage of the implementation guide is organized

More information

NATIONAL PROFILES FOR PHARMACY CONTENTS

NATIONAL PROFILES FOR PHARMACY CONTENTS NATIONAL PROFILES FOR PHARMACY CONTENTS Profile Title AfC Banding Page Pharmacy Support Worker Pharmacy Support Worker Higher Level Pharmacy Technician 4 4 Pharmacy Technician Higher level 5 5 Pharmacist

More information

QOF Quality and Productivity (QP) Indicators. Supplementary Guidance and Frequently Asked Questions for PCTs and Practices in England

QOF Quality and Productivity (QP) Indicators. Supplementary Guidance and Frequently Asked Questions for PCTs and Practices in England QOF Quality and Productivity (QP) Indicators Supplementary Guidance and Frequently Asked Questions for PCTs and Practices in England May 2011 Contents Introduction 2 Summary of QP indicators 3 Prescribing

More information

Evaluation of Pharmacy Delivery Models

Evaluation of Pharmacy Delivery Models Evaluation of Pharmacy Delivery Models As Required By House Bill 1, 84th Legislature, Regular Session, 2015 (Article II, Health and Human Services Commission, Rider 83) Health and Human Services Commission

More information

Lewisham Integrated Medicines Optimisation Service

Lewisham Integrated Medicines Optimisation Service Lewisham Integrated Medicines Optimisation Service By Kath Howes (CCG) & Kay Fahy (University Hospital Lewisham) Katherine.howes@nhs.net LIMOS: 02030493228 Seen this before??- Hoarding & Wastage The Story

More information

PROTOCOL FOR THE ADMINISTRATION OF SENNA. Formulary and Prescribing Guidelines

PROTOCOL FOR THE ADMINISTRATION OF SENNA. Formulary and Prescribing Guidelines PROTOCOL FOR THE ADMINISTRATION OF SENNA Formulary and Prescribing Guidelines Introduction This protocol allows for the administration of Senna by a registered nurse without a prescription from a doctor

More information

Ensuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING

Ensuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING Ensuring our safeguarding arrangements act to help and protect adults PRACTICE GUIDANCE FOR REPORTING MEDICATION INCIDENTS INTO SAFEGUARDING Contents Page 1.0 Purpose 2 2.0 Definition of medication error

More information

ACG GI Practice Toolbox

ACG GI Practice Toolbox ACG GI Practice Toolbox Setting Up an Ambulatory Infusion Center in Your Practice AUTHOR: David L. Limauro, MD, University of Pittsburgh Medical Center, Pittsburgh, PA INTRODUCTION: Private practices in

More information

National Cancer Action Team. National Cancer Peer Review Programme EVIDENCE GUIDE FOR: Colorectal MDT. Version 1

National Cancer Action Team. National Cancer Peer Review Programme EVIDENCE GUIDE FOR: Colorectal MDT. Version 1 National Cancer Action Team National Cancer Peer Review Programme FOR: Version 1 Introduction This evidence guide has been formulated to assist Networks and their constituent teams in preparing for peer

More information

CCG Policy for Working with the Pharmaceutical Industry

CCG Policy for Working with the Pharmaceutical Industry CCG Policy for Working with the Pharmaceutical Industry 1. Introduction Medicines are the most frequently and widely used NHS treatment and account for over 12% of NHS expenditure. The Pharmaceutical Industry

More information

Long Term Care Group Services Organizations Not Just for Nursing Home Providers Anymore

Long Term Care Group Services Organizations Not Just for Nursing Home Providers Anymore Long Term Care Group Services Organizations Not Just for Nursing Home Providers Anymore Presented by: Denny Sherrill, Vice President, GeriMed John Schutte, President, GeriMed 2:15 p.m. - 3:45 p.m., Tuesday,

More information

Supporting Children at School with Medical Conditions

Supporting Children at School with Medical Conditions Introduction Children and young people with medical conditions are entitled to a full education and have the same rights of admission to school as other children. This means that no child with a medical

More information

Systemic anti-cancer therapy Care Pathway

Systemic anti-cancer therapy Care Pathway Network Guidance Document Status: Expiry Date: Version Number: Publication Date: Final July 2013 V2 July 2011 Page 1 of 9 Contents Contents... 2 STANDARDS FOR PREPARATION AND PHARMACY... 3 1.1 Facilities

More information

Non Medical Prescribing Policy

Non Medical Prescribing Policy Non Medical Prescribing Policy Author: Sponsor/Executive: Responsible committee: Ratified by: Consultation & Approval: (Committee/Groups which signed off the policy, including date) This document replaces:

More information

NHS Lanarkshire Policy for the Availability of Unlicensed Medicines

NHS Lanarkshire Policy for the Availability of Unlicensed Medicines NHS Lanarkshire Policy for the Availability of Unlicensed Medicines Prepared by: NHS Lanarkshire Chief Pharmacist Endorsed by: Area Drug & Therapeutic Committee Previous Version/Date: Primary Policy Date:

More information

AN ACT. Be it enacted by the General Assembly of the State of Ohio:

AN ACT. Be it enacted by the General Assembly of the State of Ohio: (131st General Assembly) (Substitute House Bill Number 124) AN ACT To amend section 4729.01 and to enact sections 4723.4810, 4729.282, 4730.432, and 4731.93 of the Revised Code regarding the authority

More information

Subtitle E New Options for States to Provide Long-Term Services and Supports

Subtitle E New Options for States to Provide Long-Term Services and Supports LONG TERM CARE (SECTION-BY-SECTION ANALYSIS) (Information compiled from the Democratic Policy Committee (DPC) Report on The Patient Protection and Affordable Care Act and the Health Care and Education

More information

Community Intravenous Therapy Referral Standards

Community Intravenous Therapy Referral Standards pecialist harmacy ervice Medicines Use and afety Community Intravenous Therapy Referral tandards Background A multi-centred audit of prescribing and administration of community IV therapy across East and

More information

Tribal Best Practices and Critical Issues: Medicaid Pharmacy Reimbursement for IHS / Tribal / Urban Indian Health Programs

Tribal Best Practices and Critical Issues: Medicaid Pharmacy Reimbursement for IHS / Tribal / Urban Indian Health Programs Tribal Best Practices and Critical Issues: Medicaid Pharmacy Reimbursement for IHS / Tribal / Urban Indian Health Programs February 28, 2018 Tribal Self Governance Advisory Committee TribalSelfGov.org

More information

79th OREGON LEGISLATIVE ASSEMBLY Regular Session. Enrolled

79th OREGON LEGISLATIVE ASSEMBLY Regular Session. Enrolled 79th OREGON LEGISLATIVE ASSEMBLY--2017 Regular Session Enrolled House Bill 2527 Sponsored by Representative BUEHLER, Senator STEINER HAYWARD; Representatives HACK, KENY-GUYER, SOLLMAN, Senator MONNES ANDERSON

More information

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL MEDICINES CONTROL COUNCIL SCHEDULING OF SUBSTANCES FOR PRESCRIBING BY AUTHORISED PRESCRIBERS This document provides guidance on the process for amending the Schedules to the Medicines and Related Substances

More information

Commercial Risk Adjustment (CRA) Enrollee Health Assessment Program. Provider User Guide. Table of Contents

Commercial Risk Adjustment (CRA) Enrollee Health Assessment Program. Provider User Guide. Table of Contents Commercial Risk Adjustment (CRA) Enrollee Health Assessment Program Provider User Guide Table of Contents 1. Commercial Risk Adjustment (CRA)... 2 2. Enrollee Health Assessment (EHA) Program... 2 3. Program

More information

Summary of Benefits [Silver Access+ HMO 1750/55 OffEx] [Silver Local Access+ HMO 1750/55 OffEx]

Summary of Benefits [Silver Access+ HMO 1750/55 OffEx] [Silver Local Access+ HMO 1750/55 OffEx] Blue Shield of California is an independent member of the Blue Shield Association Summary of Benefits [Silver Access+ HMO 1750/55 OffEx] [Silver Local Access+ HMO 1750/55 OffEx] Group Plan HMO Benefit

More information

Do you suffer from diabetes? Do you want to shape the future of diabetes care?

Do you suffer from diabetes? Do you want to shape the future of diabetes care? Do you suffer from diabetes? Do you want to shape the future of diabetes care? MSD has fully funded this project which is a collaboration between MSD, Heart of England Foundation Trust, Lloyds Pharmacy

More information

Researched Medicines Industry Association of New Zealand Incorporated. Submission on Pharmacist Prescribers

Researched Medicines Industry Association of New Zealand Incorporated. Submission on Pharmacist Prescribers Researched Medicines Industry Association of New Zealand Incorporated Submission on Pharmacist Prescribers July 2010 Researched Medicines Industry Association of New Zealand Incorporated Level 8, 86-90

More information

PHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK

PHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK PHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK 0 CONTENTS Course Description Period of Learning in Practice Summary of Competencies Guide to Assessing Competencies Page 2 3 10 14 Course

More information